Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by Fmr LLC

Fmr LLC lifted its holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) by 174.5% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,540,190 shares of the company’s stock after purchasing an additional 979,110 shares during the period. Fmr LLC owned approximately 1.23% of Wave Life Sciences worth $12,630,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Wave Life Sciences by 23.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock worth $37,000 after acquiring an additional 856 shares during the last quarter. Profund Advisors LLC purchased a new stake in shares of Wave Life Sciences during the 2nd quarter worth approximately $53,000. Principal Financial Group Inc. purchased a new stake in shares of Wave Life Sciences during the 2nd quarter worth approximately $74,000. Mackenzie Financial Corp lifted its position in shares of Wave Life Sciences by 13.6% during the 2nd quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock worth $79,000 after buying an additional 1,905 shares during the last quarter. Finally, US Bancorp DE lifted its position in shares of Wave Life Sciences by 53.9% during the 3rd quarter. US Bancorp DE now owns 18,043 shares of the company’s stock worth $148,000 after buying an additional 6,316 shares during the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on WVE. Mizuho upped their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Raymond James upgraded shares of Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $13.00 to $22.00 in a research report on Wednesday, October 16th. Royal Bank of Canada upped their price target on shares of Wave Life Sciences from $7.00 to $15.00 and gave the company a “sector perform” rating in a research report on Monday, October 21st. StockNews.com downgraded shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, November 13th. Finally, B. Riley upped their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, November 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $22.22.

Insider Activity at Wave Life Sciences

In other Wave Life Sciences news, CFO Kyle Moran sold 17,146 shares of the company’s stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $9.00, for a total value of $154,314.00. Following the transaction, the chief financial officer now directly owns 19,777 shares in the company, valued at approximately $177,993. This represents a 46.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Chris Francis sold 36,000 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $576,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 453,690 shares of company stock valued at $6,425,883. Insiders own 29.10% of the company’s stock.

Wave Life Sciences Trading Up 3.0 %

Shares of NASDAQ WVE opened at $15.41 on Thursday. The stock has a market cap of $2.35 billion, a price-to-earnings ratio of -13.88 and a beta of -1.21. Wave Life Sciences Ltd. has a 52 week low of $3.50 and a 52 week high of $16.74. The company’s 50-day moving average price is $13.59 and its 200 day moving average price is $8.63.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.